ABOUT THE COMPANY
We are a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases in Asia. For the past decade, we have accumulated expertise covering the entire product development process, ranging from basic research, T cell engineering and development, and preclinical/clinical assessment. Led by industry and academic experts from our base in Singapore, we are dedicated to the commercialization and continued development of our immunotherapy products.
Mr. Stephen Lim is the CEO of Lion TCR Pte. Ltd.. He possesses more than 20 years of experience in general management, business & channel development and change management. Mr. Stephen was involved in several start-ups and business turnaround in Asia and has run two SGX-listed companies as CEO. He has experience in commercialization and distribution of medical devices in China.
Dario CAMPANA, M.D., Ph.D.
Dr. Dario Campana, M.D., Ph.D., is an expert in the field of cell therapies for cancer. He is one of the first to incorporate a key signaling ligand, 4-1BB, in chimeric antigen receptor (CAR)-T cell therapy, which has been adopted by Novartis to treat various types of leukemia. He further modified CARs to express CD16, generating T cells that can engage antibody-dependent cell cytotoxicity to boost the effects of therapeutic antibodies. He is the scientific founder of Unum Therapeutics, a pediatrics professor at the National University of Singapore, and the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy by VIVA Foundation. Dr. Campana is the scientific advisor of Lion TCR on cellular immunotherapy.
Ernesto GUCCIONE, Ph.D.
Fu-Sheng WANG, M.D., Ph.D.
Dr. Fu-Sheng WANG, M.D., Ph.D., is the Director of the Research Center for Biological Therapy, and the Beijing Institute of Infectious Diseases. He received post-doctoral training in the Department of Medical Oncology at Mount Sinai, New York University, U.S.A., and is currently the Principal Investigator for the National 973 Program in Viral Hepatitis. As a key member involved in formulating the national regulations for autologous adoptive immune therapy for patients with chronic viral hepatitis, Dr. Wang’s expertise makes him well suited as the clinical research advisor of Lion TCR.